Literature DB >> 26191244

Prognostic significance of SOX-1 expression in human hepatocelluar cancer.

Jinshu Lou1, Kai Zhang2, Jing Chen2, Yanping Gao2, Rui Wang2, Long-Bang Chen2.   

Abstract

Sex-determining region Y (SRY)-box 1 (SOX1) as a member of the SOX gene superfamily is reported to function as a tumor suppressor in hepatocelluar cancer (HCC). However, the clinicopathological and prognostic significance of SOX-1 expression in HCC is unclear. First, semi-quantitative RT-PCR and Western blot assays were performed to detect the expression of SOX-1 mRNA and protein in 15 paired of HCC tissues and corresponding nontumor tissues. Next, immunohistochemistry was performed to detect SOX-1 protein expression in another 96 cases of HCC tissues, and analyze its correlation with clincopathological factors of patients. Finally, the survival was evaluated by the Kaplan-Meier method and proportional hazards model. Results showed that the expression levels of SOX-1 mRNA and protein in HCC tissues were significantly lower than that in the corresponding nontumor tissues. Statistical analyses indicated that low SOX-1 expression was significantly correlated with higher incidence of venous or lymphatic invasion and advanced TNM stage. Also, patients with high SOX-1 expression showed better overall survival than those with low SOX-1 expression, and multivariate analysis with the Cox proportional hazards indicated that status of SOX-1 expression might be an independent prognostic factor in HCC patients. Collectively, our results indicated that downregulation of SOX-1 was correlated with poor prognosis and tumor development in HCC.

Entities:  

Keywords:  Hepatocelluar cancer (HCC); SOX-1; immunohistochemistry; overall survival; prognosis

Mesh:

Substances:

Year:  2015        PMID: 26191244      PMCID: PMC4503115     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  29 in total

Review 1.  Management of HCC.

Authors:  Carlos Rodríguez de Lope; Silvia Tremosini; Alejandro Forner; María Reig; Jordi Bruix
Journal:  J Hepatol       Date:  2012       Impact factor: 25.083

Review 2.  Sox proteins and neural crest development.

Authors:  Chang-Soo Hong; Jean-Pierre Saint-Jeannet
Journal:  Semin Cell Dev Biol       Date:  2005-07-21       Impact factor: 7.727

3.  Low SOX17 expression is a prognostic factor and drives transcriptional dysregulation and esophageal cancer progression.

Authors:  I-Ying Kuo; Ching-Chi Wu; Jia-Ming Chang; Yu-Lin Huang; Chien-Hsun Lin; Jing-Jou Yan; Bor-Shyang Sheu; Pei-Jung Lu; Wei-Lun Chang; Wu-Wei Lai; Yi-Ching Wang
Journal:  Int J Cancer       Date:  2014-01-10       Impact factor: 7.396

4.  SOX1 functions as a tumor suppressor by antagonizing the WNT/β-catenin signaling pathway in hepatocellular carcinoma.

Authors:  Chun-Ming Tsao; Ming-De Yan; Yu-Lueng Shih; Pei-Ning Yu; Chih-Chi Kuo; Wen-Chi Lin; Hsin-Jung Li; Ya-Wen Lin
Journal:  Hepatology       Date:  2012-12       Impact factor: 17.425

5.  Epigenetic inactivation of SOX1 promotes cell migration in lung cancer.

Authors:  Ning Li; Suyun Li
Journal:  Tumour Biol       Date:  2015-01-23

6.  An epigenetic marker panel for screening and prognostic prediction of ovarian cancer.

Authors:  Her-Young Su; Hung-Cheng Lai; Ya-Wen Lin; Yu-Ching Chou; Chin-Yu Liu; Mu-Hsien Yu
Journal:  Int J Cancer       Date:  2009-01-15       Impact factor: 7.396

7.  Oncogenicity of the transcription factor SOX8 in hepatocellular carcinoma.

Authors:  Siquan Zhang; Cong Zhu; Limin Zhu; Huafeng Liu; Shourong Liu; Nianbo Zhao; Jing Wu; Xiaoxiao Huang; Yujuan Zhang; Jie Jin; Ting Ji; Xianfeng Ding
Journal:  Med Oncol       Date:  2014-03-19       Impact factor: 3.064

8.  Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma.

Authors:  Xiaodong Guo; Lu Xiong; Ting Sun; Ruiyun Peng; Lin Zou; Haiyan Zhu; Jing Zhang; Hanwei Li; Jingmin Zhao
Journal:  Diagn Pathol       Date:  2012-04-19       Impact factor: 2.644

9.  Reduced expression of SOX7 in ovarian cancer: a novel tumor suppressor through the Wnt/β-catenin signaling pathway.

Authors:  Huidi Liu; Zi-Qiao Yan; Bailiang Li; Si-Yuan Yin; Qiang Sun; Jun-Jie Kou; Dan Ye; Kelsey Ferns; Hong-Yu Liu; Shu-Lin Liu
Journal:  J Ovarian Res       Date:  2014-09-05       Impact factor: 4.234

10.  A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes.

Authors:  J Gubbay; J Collignon; P Koopman; B Capel; A Economou; A Münsterberg; N Vivian; P Goodfellow; R Lovell-Badge
Journal:  Nature       Date:  1990-07-19       Impact factor: 49.962

View more
  5 in total

1.  UCHL3 promotes proliferation of colorectal cancer cells by regulating SOX12 via AKT/mTOR signaling pathway.

Authors:  Jiangning Li; Yang Zheng; Xiaofeng Li; Xue Dong; Weiyan Chen; Zhongying Guan; Chong Zhang
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

2.  Oncogenic activity of SOX1 in glioblastoma.

Authors:  Idoia Garcia; Juncal Aldaregia; Jelena Marjanovic Vicentic; Paula Aldaz; Leire Moreno-Cugnon; Sergio Torres-Bayona; Estefania Carrasco-Garcia; Laura Garros-Regulez; Larraitz Egaña; Angel Rubio; Steven Pollard; Milena Stevanovic; Nicolas Sampron; Ander Matheu
Journal:  Sci Rep       Date:  2017-04-20       Impact factor: 4.379

3.  DNA hypermethylated status and gene expression of PAX1/SOX1 in patients with colorectal carcinoma.

Authors:  Jin Huang; Zhi-Rong Tan; Jing Yu; He Li; Qiao-Li Lv; Ying-Ying Shao; Hong-Hao Zhou
Journal:  Onco Targets Ther       Date:  2017-09-26       Impact factor: 4.147

4.  Sex-determining region Y box-containing genes: regulators and biomarkers in gynecological cancers.

Authors:  Jiali Hu; Ke Li; Zhanghuan Li; Chao Gao; Fei Guo; Yingmei Wang; Fengxia Xue
Journal:  Cancer Biol Med       Date:  2019-08       Impact factor: 4.248

5.  A six-mRNA signature model for the prognosis of head and neck squamous cell carcinoma.

Authors:  Wenna Guo; Xijia Chen; Liucun Zhu; Qiang Wang
Journal:  Oncotarget       Date:  2017-10-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.